Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668846 | 0.82 | PRKCI (0.45) | PRKCIPDCD1CD274ATRATRIP | |
| SCHEMBL20593272 | 0.82 | PRKCI (0.45) | PRKCIPDCD1CD274ATRATRIP | |
| SCHEMBL16612853 | 0.81 | BRD4 (0.43) | DYRK1ACLK1CLK2CLK3CDK5 | |
| SCHEMBL23148049 | 0.79 | AXL (0.44) | PRKCIDYRK1ACLK1CLK2CLK3 | |
| SCHEMBL29722091 | 0.79 | TRPA1 (0.38) | DYRK1ACLK1CLK2CLK3CDK5 | |
| SCHEMBL23147607 | 0.79 | TRPA1 (0.38) | DYRK1ACLK1CLK2CLK3CDK5 | |
| SCHEMBL14927706 | 0.77 | ADORA2A (0.49) | PRKCIDYRK1APDCD1CD274CHEK1 | |
| SCHEMBL29138127 | 0.76 | PRKCI (0.39) | PRKCIDYRK1ARHEB | |
| SCHEMBL1835480 | 0.76 | BRD4 (0.42) | PRKCIDYRK1ABRD4MAPK1TTBK1 | |
| SCHEMBL29954439 | 0.76 | ALDH1A1 (0.38) | DYRK1ACLK1CLK2CLK3CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527774-B2 | Estrogen-related receptor alpha modulators | LEAD PHARMA HOLDING B.V. (NL) | 2026-01-20 | — | — | US | disclosed |
| US-20250268872-A2 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2025-08-28 | — | — | US | disclosed |
| EP-3994138-B1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRALPHA) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2025-04-02 | — | — | EP | disclosed |
| CN-114341135-B | Estrogen-related receptor alpha (erra) modulators | 领先制药控股公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| EP-3765008-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3765008-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | PRKCI 748/4885DYRK1A 2128/4885CLK1 3390/4885 |
| US-12527774-B2 | Estrogen-related receptor alpha modulators | ESR2, ESRRA, ESRRB | PRKCI 2747/4885DYRK1A 3169/4885CLK1 4785/4885 |
| US-20250268872-A2 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | ESRRA, ESRRB, ESR2 | PRKCI 735/4885DYRK1A 2341/4885CLK1 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.